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The evaluation of short-term prognosis after PCI of unstable angina pectoris
patients for triple antiplatelet therapy
Han Gaojie, Li Yongjun
The Second Hospital of He Bei Medical University
Objectives: Investigate the triple antiplatelet therapy on the evalua- tion of short-term
prognosis of unstable angina pectoris patients after PCI, in order to supply a clinical
evidence for patients who were treated by PCI with preoperative and postoperative
antiplatelet choices.
Methods: Selective PCI patients with UAP 302 cases (male 172 cases, females 130
cases) in our hospital were randomly divided into control group which was double
antiplatelet treatment therapy group(aspirin and clopidogrel, 151 cases ) and triple
antiplatelet therapy group (aspirin, clopidogrel and cilostazol,151 cases). The day
before PCI the dual antiplatelet therapy group was given aspirin and clopidogrel
loading capacity 300 mg, after PCI aspirin was 100 mg once a day and clopidogrel 75
mg. While the day before PCI the triple antiplatelet therapy groupe was given aspirin
and clopidogrel load capacity 300 mg, load capacity for cilostazol was 200 mg, after
PCI patients in TT were given aspirin 100 mg once a day, clopidogrel 75 mg once a
day and cilostazol 100 mg twice a day. Observing in patients with high sensitivity C
reactive protein (hs-CRP), cardiac markers, adverse cardiovascular and cerebrovas-
cular events (MACCE) and bleeding events.
Results: (1) There were no obvious differences in clinical characteristics[age, sex,
hypertension, diabetes, smoking history, proton pump inhibitors(PPI),the average
number of vascular lesions,the average number of stent implantation between the
double groups](P> 0.05). (2) Using hs-CRP as a sign of inﬂammatory injury, there
was no striking difference between the two groups before PCI 24h(4.670.56 vs
4.630.35, P¼0.633).The follow-up 24h hs-CRP there was a clear difference between
the conventional treatment group and the TT group(7.690.75 vs 6.030.63,
P<0.001). (3) Detect CK-MB and cTnI after PCI 16h, the values were signiﬁcantly
higher than the preoperative ones(double antiplatelet group CK-MB:16.803.26
vs 11.302.38;cTnI:0.180.02 vs 0.060.02;triple antiplatelet group CK-
MB:14.302.78 vs 10.903.02;cTnI:0.17 0.04 vs 0.060.02). But after 16h triple
antiplatelet group compared with dual antiplatelet group CK-MB and cTnI were
signiﬁcantly decreased (CK-MB: 16.804.3.26 vs 14.302.78, P<0.001; cTnI:
0.180.02 vs 0.170.04, P¼0.017). (4) After PCI 30 days the two groups had no
serious bleeding to stop anti- platelet therapy in patients. In the dual antiplatelet
therapy group there were 6 cases of a little bleeding and 9 cases of minor blee-
ding,while 6 cases of a little bleeding and 15 cases of minor bleeding in the triple
antiplatelet group.There was no obvious difference between the dule groups(10% vs
14%, P¼0.538). (5) Within PCI 30 days,there were 3 cases of cardiac death,9 cases
of myocardial infarction,6 patients with revascularization and 6 patients with cerebral
stroke in the dual antiplatelet therapy group.While in the triple antiplatelet group,-
there were 3 cases of myocardial infarction and 3 patients with revascularization.The
incidence of MACCE in the triple anti- platelet group was lower than dual anti-
platelet therapy group (16% vs 4%, P¼0.046).
Conclusions: Compared with dual antiplatelet therapy, preoperative PCI triple anti-
platelet therapy based on the load capacity of cilostazol can reduce postoperative
inﬂammatory reaction and the incidence of MACCE after PCI. At the same time PCI
does not increase the incidence of postoperative hemo- rrhage.
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Evidence-based Comparative Safety of Atorvastatin 10mg versus 80mg in
Chinese Atherosclerosis Patients
Li Jianping1, Hui Wang2, Na Qin2, Mengxi Chen2, Shaowen Tang2
1Department of Cardiology, Peking University First Hospital, 2Department of
Epidemiology & Biostatistics, Nanjing Medical University
Objectives: To compare the safety proﬁle of atorvastatin 80mg with that of ator-
vastatin 10mg in Chinese atherosclerosis patients based on systematic review.
Methods: Literatures were retrieved from PubMed, EMBASE, CENTRAL,
CBMDisc, CMCI, CNKI, VIP and Wanfang database (March 2013). The quality
assessment, data extraction and veriﬁcation of collected literatures were conducted by
two reviewers independently. Review Manager 5.2.1 and Indirect Treatment Com-
parisons (ITC) software were applied to compute direct and indirect effects of adverse
reactions. Then the results were described by Odds ratios (OR) and 95% conﬁdence
intervals (95% CI) in each comparison group.
Results: In total 19 qualiﬁed literatures with 1761 atherosclerosis patients were
included. The maximum treatment period was 5 years. Adverse reactions such as
drug-induced abnormal liver function, myalgia, creatine phosphokinase and gastro-
intestinal reactions were investigated in 19, 12, 6 and 6 studies respectively. The
numbers of direct comparisons in drug-induced abnormal liver function of 10mg vs
80mg, 10mg vs 20mg, 20mg vs 80mg, 10mg vs 40mg, and 40mg vs 80mg were 2, 6,
4, 7, and 1, respectively. The OR of direct effect of drug-induced abnormal liver
function in 10mg vs 80mg was 0.43 (95% CI 0.06-2.97). Similarly, the OR of direct
effect in 10mg vs 20mg, 20mg vs 80mg, and 10mg vs 40mg were 0.54(95% CI 0.23-
1.26), 0.60(95% CI 0.15-2.41), and 0.32(95% CI 0.10-1.01), respectively. No drug-
induced abnormal liver function was observed in direct comparisons of 40mg vs
80mg. To compare the indirect effects, setting 20mg as a common comparator in ITC,
the OR of indirect effect in 10mg vs 80mg group was 0.324 (95% CI 0.064-1.651).
Changing the common comparator from 20mg to 40mg, the OR of indirect effect was
dropped to 0.298 (95% CI 0.005-17.263). No drug-induced myalgia was described inC204 JACC Vol 64/16/Suppl C j October 16–1direct comparisons of 10mg vs 80mg, and setting 20mg as a common comparator, the
OR of indirect effect of drug-induced myalgia in 10mg vs 80mg was 0.105 (95% CI
0.006-1.753).
Conclusions: Our results did not ﬁnd signiﬁcant differences between 10mg atorvas-
tatin group and 80mg atorvastatin group in Chinese atherosclerosis patients for
drug-induced abnormal liver function and myalgia based on the results of direct and
indirect comparison. Similarly, no signiﬁcant difference was found between 10mg
and 40mg in drug-induced abnormal liver function based on the results of direct
comparison.
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Effects of heart rate control with ivabradine plus beta-blocker on exercise
tolerance in patients after Q-wave myocardial infarction with early left
ventricular systolic dysfunction
Xu Yao, Bezrodnyi Andrii
Bogomolets National Medical University, Kyiv, Ukraine
Objectives: To investigate the effects of heart rate (HR) control with combination of
ivabradine and beta-blocker versus uptitration of beta-blocker on exercise tolerance in
patients after Q-wave myocardial infarction (MI) with early left ventricular ejection
fraction (LVEF) <45% at 6-month follow-up.
Methods: In single-blind parallel-group study 28 patients with a ﬁrst Q-wave MI
and early LVEF 30-45%, sinus rhythm > 80 bpm, Killip class I-II, after reperfusion
therapy by percutaneous coronary intervention in 12 patients (42.9%) and throm-
bolysis in 16 (57.1%) were randomized into 2 groups. As part of standard therapy,
all patients at the time of hospital admission received metoprolol tartrate 12.5 mg
bid. Apart from metoprolol tartrate (up-titrated to 25 mg bid at day 5, average daily
dose 55.31.7 mg), at day 5 patients in group 1 (n¼16) received ivabradine 2.5 mg
bid (up-titrated to 7.5 mg bid, average daily dose 11.31.5 mg). In group 2 (n¼12)
metoprolol tartrate was up-titrated to 75 mg bid (average daily dose 105.45.2
mg). The two groups were similar for clinical characteristics. No difference was
evidenced in initial resting HR and LVEF between two groups at entry (87.31.6
vs 86.71.5 bpm, 38.51.4 vs 38.91.5%, respectively, all P>0.05). Besides
LVEF at admission, day 28 and after 6 months, symptom-limited treadmill test
(Bruce protocol) to conduct stress tests at the trough of drug activity (12 h after last
intake of ivabradine and metoprolol tartrate) was performed at day 28 and after
6 months.
Results: Resting HR decreased similarly in both groups (at day 28 - 62.51.5 vs
63.71.4 bpm, after 6 months - 61.31.5 vs 62.81.6 bpm, all P>0.05). Group 1
showed a signiﬁcant increase in LVEF (at day 28 - increased to 46.31.5%, after
6 months - up to 49.11.7%, all P<0.01). In group 2 LVEF didn’t change signiﬁ-
cantly (at day 28 - 42.11.5%, after 6 months - 43.21.6%, all P>0.05). The dif-
ference in LVEF at day 28 after initial treatment between the 2 groups was signiﬁcant
(P<0.01). After 6 months, threshold load capacity, exercise duration and chronotropic
reserve signiﬁcantly improved in both groups in comparison to basal levels (in group
1 - 6.30.4 vs 5.00.3 MET, 257.312.6 vs 209.412.4 s, 54.22.8 vs 42.32.5
bpm, all P<0.01; in group 2 - 5.20.3 vs 4.10.3 MET, 211.312.5 vs
168.212.2 s, 43.82.9 vs 34.52.8 bpm, respectively, all P<0.05). However, in
group 1 compared to group 2 higher threshold load capacity, exercise duration and
chronotropic reserve (all P<0.01) were attained in spite of higher HR at peak exercise
(at day 28 - 107.32.6 vs 98.62,5 bpm, after 6 months - 129.52.7 vs 106.82.6
bpm, respectively, all P<0.01).
Conclusions: In patients after Q-wave MI with early LVEF < 45%, ivabradine in
combination with low dose metoprolol tartrate, besides improvement in left ventric-
ular systolic function, increased exercise tolerance at 6-month follow-up.
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The systematic review on Wendan decoction’s clinical efﬁcacy in the treatment of
Arrhythmia
Ma Nana, Li Ping
Third afﬁliated hospital of Beijing university of Chinese medicine
Objectives: Although the research about WenDan decoction treatment of arrhythmia a
lot, it is lack of rigorous, system evaluation, also cannot form the objective evidence.
Therefore this research will evaluate the clinical efﬁcacy and safety of Wendan
decoction in the treatment of arrhythmia, provide new ideas and the new method for
clinical treatment of arrhythmia.
Methods: According to the method of Cochrane systematic review, Literatures from
WANFANG database, VIP database, the full text of the CNKI database, CBM
database and Medline database regarding randomized controlled trials and half a
randomized controlled trials of Wendandecoction in the treatment of arrhythmia were
reviewed. As all searches end in 2014. Related literatures were selected and analyzed
according to the standards. The method ologicalquality of the trials was assessed by
quality evaluation standard which was recommendated by the Cochrane systematic
review manual 5.2 and evaluation was performed with software RevMan5.2.And
heterogeneity test, sensitivity and bias analysis was carried on.
Results: Eleven randomized controlled trials meting the inclusion criteria were
selected and reviewed. All selected trials are in Chinese. A total of 990 patients, the
treatment group of 534 people, the control group of 456 people. Only 2 trial is in high
quality, the others are not. Meta-analysis results shown: in the comparison with
control group ,the clinical total effective rate of the Wendan decoction in the treatment9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
of arrhythmiahas has statistical signiﬁcance, OR¼3.39, 95% CI 2.30-5.00, which
means that the clinical total effective rate of the treatment of arrhythmia mainly using
Wendan decoction was superior to the control group; in the comparison with control
group, the symptoms improved efﬁciency of the Wendan decoction in the treatment of
arrhythmiahas has statistical signiﬁcance, OR¼2.65, 95% CI 1.24-5.67, which means
that the symptoms improved efﬁciency of the treatment of arrhythmia mainly using
Wendan decoction was superior to the control group; in the comparison with control
group, the electrocardiogram improved efﬁciency of the Wendan decoction in the
treatment of arrhythmiahas also has statistical signiﬁcance, OR¼2.65, 95% CI 1.24-
5.67, which means that the electrocardiogram improved efﬁciency of the treatment of
arrhythmia mainly using Wendan decoction was superior to the control group. The
funnel plot point out that there may be publication bias. The results of sensitivity
analysis are the same as the original. The results analyzed by Meta-analysis were
stable and reliable.
Conclusions: Wendan decoction is effective to treat arrhythmia,improve the
clinical symptoms and electrocardiogram of arrhythmia. But because the quality
and quantity of the research are limited, further conﬁrmation with clinical ran-
domized controlled trials of high quality, large sample and long-term follow-up are
needed.
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Effects of Inhaled iloprost on gas exchange and hemodynamics in patients with
pulmonary hypertension due to lung diseases
Wang Lan, Bai Lei, He Jing, Zhao Qinhua, Liu Jinming
Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji
University, School of Medicine, Shanghai, China
Objectives: To investigate the acute effects of inhaled iloprost on V/Q matching, and
hemodynamics in patients with pulmonary hypertension (PH) due to chronic lung
diseases.
Methods: Sixty-nine patients with chronic lung diseases and PH were diagnosed by
right heart catheterization (RHC).All patients received a single dose of 20mg iloprost
during the process of RHC, Cardiopulmonary data included hemodynamic parameters
and PaO2, PaCO2, SaO2, P(A-a) O2, venous admixture/shunt fraction (Qs$/Qt) were
measured or calculated at baseline, and 20 minutes after inhalation iloprost
respectively.
Results: nhalated iloprost caused a decrease in mPAP from 44.510.5mmHg to
41.611.4mmHg, and PVR from 7.63.6 Wood Units to 6.63.9 Wood Units
(meanSD, P<0.001, respectively), cardiac index increase from 3.20.8 L/min/m2 to
3.51.0L/min/m2 (meanSD, P<0.001). Arterial blood gas and calculated Qs$/Qt$
were maintained after iloprost. No adverse effects on systemic blood pressure were
seen.
Conclusions: Iloprost inhalation was safe in patients with PH due to lung diseases,
and improved hemodynamics but didn’t affect V/Q matching and gas change.
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Comparison for the effect on cardiac output during loading time between
dexmedetomidine and propofol in postoperative patients
Lin Zong-Qin1, Jiang Zhi-Yi2, Chen Juan2, Ouyang Bin2, Guan Xiang-Dong2,
Chen Min-Ying2
1General Intensive Care Unit, Huiya Hospital of The First Afﬁliated Hospital,
Sun Yat-Sen University, 2Surgical Intensive Care Unit(SICU), The First Afﬁliated
Hospital, Sun Yat-Sen University
Objectives: To compare the change of cardiac output(CO) during loading dose were
injecting between dexmedetomidine and propofol in patients after major abdominal
surgery.
Methods: 74 patients after major abdominal surgery were enrolled. They were
randomly divided into two groups: Dexmedetomidine group (DEX group) or Propofol
group (PRO group), 37 cases in each group. Depth of sedation was monitored using
the bispectral index (BIS), CO and other cardiodynamic date were recorded through
“Vigileo” and cardiogram monitor. When the patients could be roused, a loading
dose of fentanyl was injected at 0.0007mg/kg, followed by continuous infusion at
0.3mg/kg/h for additional analgesia. DEX group received 1 mg/kg loading dose fol-
lowed by continuous infusion of 0.3mg/kg/h. PRO group received 0.5mg/kg loading
dose followed by continuous infusion at 0.5mg/kg/h. Dose were adjusted to accom-
plish BIS value 70-80. BIS value, HR (Heart rate), SV (stroke volume) and CO were
recorded at 0min, 5min, 10min, 30min.
Results: Both groups were able to achieve the target sedation level according to BIS
value. There were no differences in BIS values between DEX group and PRO group
(61.2312.73 vs 62.5513.67 P¼0.127). After the loading dose, DEX group caused
HR decrease signiﬁcantly than PRO group [P¼0.006]. SV showed different effect in
both groups, SV augmented signiﬁcantly in DEX group after the loading dose, as SV
decreased signiﬁcantly in PRO group. SV were signiﬁcantly decreased in PRO groups
than DEX groups (6423 vs 9029ml, P¼0.008) in the ﬁfth minutes. HR decreased
signiﬁcantly in DEX group during the loading dose period, HR decreased slightly in
PRO group, HR were signiﬁcant different between the two groups (7214 vs
8415bpm, P¼0.006). CO declined signiﬁcantly in groups comparing to the level
before the sedation (PDex<0.001, PPro<0.001). CO were signiﬁcantly decreased in
PRO groups than DEX groups in the ﬁfth minutes (5.41.7 vs 6.42.0 L/min,
P<0.05).JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CConclusions: Propofol can signiﬁcant decrease cardiac output than dexmedetomidine
during the loading time in the patients after major abdominal surgery. So monitoring
the cardiodynamics changes carefully during sedation are required.
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Effect of different dose of Statins on the Antiplatelet Potency of Clopidogrel in
Patients with Acute Myocardial Infarction
Tan Gangwen1, Wu tongguo1
1Guangzhou Red Cross Hospital, 2Jinan University
Objectives: Comparison of the inﬂuence on the platelet aggregation of clopidogrel
combined with different metabolic pathways statins in patients with acute myocardial
infarction.
Methods: From May 2013 to November 2013, there were 80 patients with acute
myocardial infarction treated with emergency PCI enrolled into this study. They were
randomly divided into the atorvastatin group (group A 40 cases); rosuvastatin group
(group B 40 cases). All patients chewed Aspirin 300mg and received clopidogrel
300mg before emergency PCI. Patients in group A received atorvastatin 80mg, Group
B received rosuvastatin 40mg before emergency PCI. Patients in group A received
atorvastatin 40mg/qd and patients in group B received rosuvastatin 20mg/qd after PCI.
All patients received dual antiplatelet therapy with aspirin 100mg/qd and clopidogrel
75mg/qd.Statins and clopidogrel were given before breakfast. The platelet aggregation
rate was measured with whole blood impedance aggregometry on the 7 days and 30
days. We observed the major adverse cardiovascular events (MACE): cardiac death,
recurrent angina, recurrent myocardial infarction, target vessel revascularization and
deterioration of cardiac function in patients after 30 days. We compared the difference
of platelet aggregation and MACE rate between the two groups. Testing the alanine
aminotransferase, creatinine, total cholesterol and low-density lipoprotein in the ﬁrst
24 hours and 30 days after PCI and recording the quantity of patients who had muscle
pain , headache, and so on after 30 days to evaluate the effects of lipid-lowering and
drug safety.
Results: (1).After PCI, on the 7th day and 30th day, we compared the platelet ag-
gregation of group A with group B. The result were (3.093.99 vs 3.794.20
P¼0.45) and (2.593.48 vs 2.994.20 P¼0.6). The platelet aggregation of group B
was slightly higher than group A in the both time but no statistical difference. (2) After
30 days, there were 9 patients (22.5%) with recurrent angina, 3 patients (7.5%) with
deterioration of heart function in group A and 5 patients (12.5%) with recurrent
angina, 4 patients (10 %) with deterioration of heart function in group B. There was no
signiﬁcant difference between the two groups of patients in adverse events and overall
MACE (P> 0.05). (3) After 30 days the level of patients’ TC and LDL-C was
decreased signiﬁcantly (P<0.05). According to the level of LDL-C <1.8mmol / l or
LDL-C decreased by 50% compared to the admission, we compared the percentage of
patients who’s level of LDL-C reached the goal in the two groups (55% vs 62.5%
P¼0.49). (4) The level of patients’ ALT and Cr were no signiﬁcant difference
compared to the admission (P>0.05). There was one patients (2.5%) with
ALT>3ULN in group A and 0 in group B. There was no patient with CK>5ULN.
Conclusions: The effect of different dose of statins on the antiplatelet potency of
clopidogrel inpatients with acute myocardial infarction was similar.
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Nesiritide fails to reduce the mortality of patients with acute decompensate heart
failure: an updated systematic review and cumulative meta-analysis
Bin Yan1, Liyuan Peng2, Xiaojing Zhao1, Hsingchun Chung3, Lijun Li1,
Lingfang Zeng4, Heanyeeong5, Gang Wang1
1Department of Emergency Medicine, the Second Afﬁliated Hospital, Xi’an Jiaotong
University School of Medicine, Xi’an, China, 2Department of Cardiology, the Second
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3Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung
County, Taiwan, 4Cardiovascular Division, King’s College London, British Heart
Foundation Centre, London, United Kingdom, 5Department of Cardiology, Khoo
Teck Puat Hospital, Singapore
Objectives: Nesiritide is prescribed to the patients with acute decompensate heart
failure (ADHF) with dyspnea according to 2012 European Society of Cardiology
(ESC) guidelines. However, a few randomized, controlled trials (RCTs) were carried
out in recent years and there has been conﬂicting reports on the effects of Nesiritide to
improve the rate of mortality and rehospitalization. Therefore, we conducted a meta-
analysis with the addition of new RCTs to produce a more reliable conclusion about
the beneﬁts received from the short- and long-term Nesiritide therapy in adults with
ADHF. Additionally, a cumulative meta-analysis on how evidence for Nesiritide has
evolved in the treatment of ADHF was performed.
Methods: To identify RCTs that evaluated the mortality and adverse events on adults
with ADHF after Nesiritide therapy, extensive searches were carried out within
MEDLINE, EMBASE, CINAHL, SIGLE, Web of Science and the Cochrane Central
Register of Controlled Trials (through August 10, 2013). When necessary, searches of
bibliographies using Medical Subject Heading terms and a standardized protocol were
also performed. Two independent reviewers identiﬁed trials, extracted data, and
assessed risk of bias.
Results: A total of 10213 patients with ADHF in ﬁfteen trials were included and
divided into the Nesiritide group (Nesiritide plus conventional treatment) and theardiovascular Disease Clinical Research C205
